Risk factors for infliximab-induced infusion reactions based on a retrospective study of medical information

被引：0
作者：
Amemiya, Takahiro [1 ]
Suzuki, Hiroshi [1 ]
机构：
[1] Univ Tokyo Hosp, Dept Pharm, 7-3-1 Hongo,Bunkyo Ku, Tokyo 1138655, Japan
来源：
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS | 2024年 / 62卷 / 07期
关键词：
Key infliximab - infusion reactions - risk factor --reactive protein; PSORIASIS;
D O I：
10.5414/CP204568
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Objective: Infliximab is indicated for a wide range of diseases, and infusion reactions (IRs) have been reported after infliximab administration in 17.6% of patients in clinical practice. This study aimed to identify the risk factors for IRs before the administration of infliximab based on available patient information. Materials and methods: We retrospectively analyzed patients treated with infliximab. Data were compared between patients with and without IRs immediately before initiation of infliximab. (odds ratio (OR), 2.150; 95% confidence interval (CI), 1.329 - 3.477; p = 0.002) before infliximab administration was a significant risk factor for developing an IR. Conclusion: Patients with elevated CRP levels before therapy initiation may require more careful monitoring after infliximab administration.
引用
收藏
页码：307 / 310
页数：4
相关论文
共 14 条
  • [1] Incidence and Management of Infusion Reactions to Infliximab in a Prospective Real-world Community Registry
    Choquette, Denis
    Faraawi, Rafat
    Chow, Andrew
    Rodrigues, Jude
    Bensen, William J.
    Nantel, Francois
    [J]. JOURNAL OF RHEUMATOLOGY, 2015, 42 (07) : 1105 - 1111
  • [2] Incidence of Infusion Reactions and Clinical Effectiveness of Intravenous Golimumab Versus Infliximab in Patients with Rheumatoid Arthritis: The Real-World AWARE Study
    Curtis, Jeffrey R.
    Chakravarty, Soumya D.
    Black, Shawn
    Kafka, Shelly
    Xu, Stephen
    Langholff, Wayne
    Parenti, Dennis
    Greenspan, Andrew
    Schwartzman, Sergio
    [J]. RHEUMATOLOGY AND THERAPY, 2021, 8 (04) : 1551 - 1563
  • [3] Complement inhibition: A possible therapeutic approach in the fight against Covid-19
    Deravi, Niloofar
    Ahsan, Elahe
    Fathi, Mobina
    Hosseini, Parastoo
    Yaghoobpoor, Shirin
    Lotfi, Ramin
    Pourbagheri-Sigaroodi, Atieh
    Bashash, Davood
    [J]. REVIEWS IN MEDICAL VIROLOGY, 2022, 32 (04)
  • [4] Clinical development methodology for infusion-related reactions with monoclonal antibodies
    Doessegger, Lucette
    Banholzer, Maria Longauer
    [J]. CLINICAL & TRANSLATIONAL IMMUNOLOGY, 2015, 4
  • [5] Critical Care Management of Toxicities Associated With Targeted Agents and Immunotherapies for Cancer
    Gutierrez, Cristina
    McEvoy, Colleen
    Munshi, Laveena
    Stephens, R. Scott
    Detsky, Michael E.
    Nates, Joseph L.
    Pastores, Stephen M.
    [J]. CRITICAL CARE MEDICINE, 2020, 48 (01) : 10 - 21
  • [6] Kerdel FA, 2014, SEMIN CUTAN MED SURG, V33, pS31, DOI 10.12788/j.sder.0066
  • [7] Infliximab-Related Infusion Reactions: Systematic Review
    Lichtenstein, Lev
    Ron, Yulia
    Kivity, Shmuel
    Ben-Horin, Shomron
    Israeli, Eran
    Fraser, Gerald M.
    Dotan, Iris
    Chowers, Yehuda
    Confino-Cohen, Ronit
    Weiss, Batia
    [J]. JOURNAL OF CROHNS & COLITIS, 2015, 9 (09) : 806 - 815
  • [8] A Systematic Review on Infliximab Biosimilar SB2: From Pre-Clinical Data to Real-World Evidence
    Macaluso, Fabio Salvatore
    Cummings, J. R. Fraser
    Atreya, Raja
    Choi, Jaeyun
    Orlando, Ambrogio
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2022, 22 (02) : 203 - 223
  • [9] Antibodies to Infliximab and Risk of Infusion Reactions in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
    O'Meara, Sorcha
    Nanda, Kavinderjit S.
    Moss, Alan C.
    [J]. INFLAMMATORY BOWEL DISEASES, 2014, 20 (01) : 1 - 6
  • [10] European S3-Guidelines on the systemic treatment of psoriasis vulgaris
    Pathirana, D.
    Ormerod, A. D.
    Saiag, P.
    Smith, C.
    Spuls, P. I.
    Nast, A.
    Barker, J.
    Bos, J. D.
    Burmester, G-R
    Chimenti, S.
    Dubertret, L.
    Eberlein, B.
    Erdmann, R.
    Ferguson, J.
    Girolomoni, G.
    Gisondi, P.
    Giunta, A.
    Griffiths, C.
    Hoenigsmann, H.
    Hussain, M.
    Jobling, R.
    Karvonen, S-L
    Kemeny, L.
    Kopp, I.
    Leonardi, C.
    Maccarone, M.
    Menter, A.
    Mrowietz, U.
    Naldi, L.
    Nijsten, T.
    Ortonne, J-P
    Orzechowski, H-D
    Rantanen, T.
    Reich, K.
    Reytan, N.
    Richards, H.
    Thio, H. B.
    van de Kerkhof, P.
    Rzany, B.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2009, 23 : 1 - 70
12